1. Home
  2. GBX vs OMER Comparison

GBX vs OMER Comparison

Compare GBX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenbrier Companies Inc. (The)

GBX

Greenbrier Companies Inc. (The)

HOLD

Current Price

$37.46

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$16.69

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBX
OMER
Founded
1974
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
GBX
OMER
Price
$37.46
$16.69
Analyst Decision
Sell
Buy
Analyst Count
3
3
Target Price
★ $45.33
$27.50
AVG Volume (30 Days)
289.6K
★ 1.2M
Earning Date
10-26-2026
11-12-2026
Dividend Yield
★ 3.52%
N/A
EPS Growth
28.02
★ 98.15
EPS
★ 2.21
0.77
Revenue
★ $3,240,200,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.54
$73.59
P/E Ratio
★ $17.58
$20.94
Revenue Growth
★ N/A
N/A
52 Week Low
$37.61
$6.24
52 Week High
$59.19
$21.24

Technical Indicators

Market Signals
Indicator
GBX
OMER
Relative Strength Index (RSI) 29.88 34.83
Support Level $37.61 $10.82
Resistance Level $43.90 $19.81
Average True Range (ATR) 1.00 0.80
MACD 0.07 -0.41
Stochastic Oscillator 33.83 6.26

Price Performance

Historical Comparison
GBX
OMER

About GBX Greenbrier Companies Inc. (The)

Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: